Chromadex Corp (NASDAQ:CDXC) CEO Frank L. Jaksch, Jr. sold 28,379 shares of the firm’s stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $6.52, for a total transaction of $185,031.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Chromadex Corp (CDXC) traded down $0.17 during trading hours on Friday, hitting $6.18. 248,113 shares of the stock traded hands, compared to its average volume of 335,758. Chromadex Corp has a 1-year low of $2.26 and a 1-year high of $7.24. The company has a quick ratio of 4.12, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $332.47, a P/E ratio of -26.87 and a beta of 1.37.
Large investors have recently bought and sold shares of the company. Thompson Davis & CO. Inc. acquired a new stake in shares of Chromadex during the third quarter worth $128,000. Goldman Sachs Group Inc. lifted its stake in shares of Chromadex by 870.6% during the second quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock worth $698,000 after buying an additional 163,817 shares during the period. Finally, Granite Investment Partners LLC lifted its stake in shares of Chromadex by 5.7% during the third quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock worth $1,076,000 after buying an additional 13,599 shares during the period. Institutional investors and hedge funds own 6.08% of the company’s stock.
Several equities research analysts have weighed in on the stock. HC Wainwright set a $8.00 target price on shares of Chromadex and gave the company a “buy” rating in a research note on Friday, December 15th. Zacks Investment Research downgraded shares of Chromadex from a “buy” rating to a “hold” rating in a research note on Wednesday, November 29th. ValuEngine downgraded shares of Chromadex from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Ladenburg Thalmann Financial Services assumed coverage on shares of Chromadex in a research note on Monday, September 25th. They issued a “buy” rating and a $7.00 target price for the company. Finally, BidaskClub downgraded shares of Chromadex from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $7.50.
WARNING: This story was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/01/13/chromadex-corp-cdxc-ceo-frank-l-jaksch-jr-sells-28379-shares.html.
Chromadex Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.